Hepatitis B Functional Cure Research

What Would a Functional Cure for Hepatitis B Mean?

Chronic hepatitis B is difficult to cure because the virus can persist inside liver cells as covalently closed circular DNA, a stable viral template that current approved drugs do not reliably eliminate. Today, first-line medicines such as tenofovir and entecavir can strongly suppress viral replication and reduce the risk of cirrhosis and liver cancer, but many patients need long-term or lifelong therapy.

A functional cure is different from sterilizing eradication. In clinical research, it generally refers to sustained hepatitis B surface antigen loss, with or without protective antibody development, and durable control of viral DNA after treatment stops. That endpoint matters because it could reduce long-term medication burden while lowering the risk of progressive liver disease.

Which New Treatment Strategies Are Being Studied?

Several investigational approaches are being tested, including RNA interference therapies, antisense oligonucleotides, capsid assembly modulators, therapeutic vaccines, and immune-modulating drugs. These treatments target different steps in the hepatitis B life cycle or the exhausted immune response that allows chronic infection to persist.

The most promising direction is combination therapy. A drug that reduces viral proteins may make it easier for the immune system to recognize infected cells, while a backbone antiviral can keep viral replication suppressed. This is why hepatitis B research is increasingly borrowing the logic of HIV and hepatitis C treatment: durable control may require hitting the virus from more than one angle.

How Could This Change Care for Patients?

For patients, the key question is not only whether a functional cure is biologically possible, but whether it can be achieved safely across diverse groups, including people with cirrhosis, long-standing infection, or coexisting metabolic liver disease. Trials must also show that stopping therapy after a response does not lead to dangerous viral rebound or liver inflammation.

Public health impact could be substantial. WHO estimates that chronic hepatitis B affects hundreds of millions of people worldwide and remains a major cause of liver cancer and liver-related death. Even a functional cure suitable for a subset of patients would represent a major step beyond indefinite viral suppression.